1. Home
  2. RVNC vs ZNTL Comparison

RVNC vs ZNTL Comparison

Compare RVNC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVNC
  • ZNTL
  • Stock Information
  • Founded
  • RVNC 1999
  • ZNTL 2014
  • Country
  • RVNC United States
  • ZNTL United States
  • Employees
  • RVNC N/A
  • ZNTL N/A
  • Industry
  • RVNC Biotechnology: Pharmaceutical Preparations
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVNC Health Care
  • ZNTL Health Care
  • Exchange
  • RVNC Nasdaq
  • ZNTL Nasdaq
  • Market Cap
  • RVNC 292.5M
  • ZNTL 300.4M
  • IPO Year
  • RVNC 2014
  • ZNTL 2020
  • Fundamental
  • Price
  • RVNC $3.96
  • ZNTL $4.29
  • Analyst Decision
  • RVNC Buy
  • ZNTL Buy
  • Analyst Count
  • RVNC 9
  • ZNTL 7
  • Target Price
  • RVNC $12.00
  • ZNTL $13.14
  • AVG Volume (30 Days)
  • RVNC 1.9M
  • ZNTL 3.0M
  • Earning Date
  • RVNC 08-06-2024
  • ZNTL 08-07-2024
  • Dividend Yield
  • RVNC N/A
  • ZNTL N/A
  • EPS Growth
  • RVNC N/A
  • ZNTL N/A
  • EPS
  • RVNC N/A
  • ZNTL N/A
  • Revenue
  • RVNC $236,645,000.00
  • ZNTL $40,560,000.00
  • Revenue This Year
  • RVNC $20.63
  • ZNTL N/A
  • Revenue Next Year
  • RVNC $34.80
  • ZNTL N/A
  • P/E Ratio
  • RVNC N/A
  • ZNTL N/A
  • Revenue Growth
  • RVNC 54.59
  • ZNTL N/A
  • 52 Week Low
  • RVNC $2.30
  • ZNTL $3.27
  • 52 Week High
  • RVNC $24.87
  • ZNTL $29.03
  • Technical
  • Relative Strength Index (RSI)
  • RVNC 68.64
  • ZNTL 34.29
  • Support Level
  • RVNC $2.40
  • ZNTL $3.83
  • Resistance Level
  • RVNC $2.75
  • ZNTL $4.27
  • Average True Range (ATR)
  • RVNC 0.29
  • ZNTL 0.42
  • MACD
  • RVNC 0.19
  • ZNTL 0.30
  • Stochastic Oscillator
  • RVNC 79.79
  • ZNTL 67.11

About RVNC Revance Therapeutics Inc.

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Share on Social Networks: